Search Results

You are looking at 31 - 40 of 252 items for :

  • "Acute myeloid leukemia" x
  • Refine by Access: All x
Clear All
Full access

QIM19-137: Effect of Socioeconomic Factors on Survival in Veterans With Acute Myeloid Leukemia

Falgun Mahendrakumar Modhia, Sarah E. Johnston, Daniel Zhao, Ankur Mody, and Mohammad O. Khalil

Background: There is limited information about socioeconomic factors effect on survival in veterans with acute myeloid leukemia (AML). Few studies published between the 1960s and 1980s suggested higher risks for leukemia mortality among veterans

Full access

Care Patterns and Barriers to Outpatient Care for Adults With AML Following Intensive Chemotherapy at NCCN Member Institutions

Anna B. Halpern, Jessica M. Sugalski, Lindsey Bandini, Megan Othus, F. Marc Stewart, and Roland B. Walter

Background Adults with acute myeloid leukemia (AML) typically remain hospitalized following intensive induction therapy while cytopenic due to infection risks, toxicity monitoring, and transfusion needs. However, this care strategy has important

Full access

CGE19-065: Number of Somatic Mutations Is an Independent Predictor of Overall Survival in Acute Myeloid Leukemia

Zin W. Myint, Rani Jayswal, Ranjana Arora, Gregory P. Monohan, Amit Goldberg, Roger Fleischman, Roger Herzig, Hayder Saeed, Gerhard C. Hildebrandt, and Reshma Ramlal

Purpose: Acute myeloid leukemia (AML) is characterized by multiple somatically acquired mutations that affect genes of different functional categories. It has been well established in myelodysplastic syndrome (MDS) that the cumulative number of

Full access

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology

The incidence of leukemia, along with its precursor, myelodysplasia, appears to be rising, particularly in the population over age 60. Recently an expanded panel of clinicians from the NCCN member institutions joined to update guidelines for the treatment of acute myeloid leukemia. Although there are some areas in which clinical trials have led to significant improvements in treatment, for the most part, recent trials have only served to highlight the continued need for innovative strategies to overcome this disease. These guidelines focus on outlining reasonable treatment options based on the information available.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology

Roswell Park Cancer Institute

Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Rafael Bejar

, for those with higher-risk MDS that evolves into acute myeloid leukemia (AML), overall survival (OS) is significantly reduced. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Rafael Bejar, MD, PhD, Associate Professor, UC San Diego Moores

Full access

Growth Factors in Leukemia

Olga Frankfurt and Martin S. Tallman

, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718

Full access

Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant

Jeffrey E. Lancet and Sergio Giralt

The authors have received research funding from Pharmion and are consultants for MGI Pharma. References 1. Surveillance, Epidemiology, and End Results (SEER) Program . Acute myeloid leukemia incidence for 2000-2004 . National

Full access

Long-Term Outcomes of Myeloid Growth Factor Treatment

Gary H. Lyman and David C. Dale

) than control patients who did not receive prophylaxis. Cancer chemotherapeutic agents are associated with an increased risk of acute myeloid leukemia (AML). 6 , 7 Several common chemotherapeutic agents are considered to be leukemogenic 8 – 13

Full access

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation

Juliana E. Hidalgo-López, Rashmi Kanagal-Shamanna, L. Jeffrey Medeiros, Zeev Estrov, C. Cameron Yin, Srdan Verstovsek, Sergej Konoplev, Jeffrey L. Jorgensen, Mohammad M. Mohammad, Roberto N. Miranda, Chong Zhao, John Lee, Zhuang Zuo, and Carlos E. Bueso-Ramos

Driver gene mutation status has been incorporated into the classification and prognostic assessment of patients with acute myeloid leukemia (AML) and, in some cases, these data are used for treatment decisions. 1 JAK2 is a nonreceptor tyrosine